SI0781776T1 - Water soluble rapamycin esters - Google Patents
Water soluble rapamycin estersInfo
- Publication number
- SI0781776T1 SI0781776T1 SI9630585T SI9630585T SI0781776T1 SI 0781776 T1 SI0781776 T1 SI 0781776T1 SI 9630585 T SI9630585 T SI 9630585T SI 9630585 T SI9630585 T SI 9630585T SI 0781776 T1 SI0781776 T1 SI 0781776T1
- Authority
- SI
- Slovenia
- Prior art keywords
- water soluble
- soluble rapamycin
- rapamycin esters
- esters
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US933895P | 1995-12-27 | 1995-12-27 | |
EP96309369A EP0781776B1 (en) | 1995-12-27 | 1996-12-20 | Water soluble rapamycin esters |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0781776T1 true SI0781776T1 (en) | 2003-06-30 |
Family
ID=21737027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9630585T SI0781776T1 (en) | 1995-12-27 | 1996-12-20 | Water soluble rapamycin esters |
Country Status (27)
Country | Link |
---|---|
US (2) | US5780462A (ru) |
EP (1) | EP0781776B1 (ru) |
JP (1) | JP4080560B2 (ru) |
KR (1) | KR100444003B1 (ru) |
CN (1) | CN1088710C (ru) |
AR (1) | AR005421A1 (ru) |
AT (1) | ATE233769T1 (ru) |
AU (1) | AU702750B2 (ru) |
BR (1) | BR9606173A (ru) |
CA (1) | CA2193329C (ru) |
CY (1) | CY2377B1 (ru) |
CZ (1) | CZ293711B6 (ru) |
DE (1) | DE69626481T2 (ru) |
DK (1) | DK0781776T3 (ru) |
ES (1) | ES2189858T3 (ru) |
HK (1) | HK1002864A1 (ru) |
HU (1) | HUP9603582A3 (ru) |
IL (1) | IL119921A (ru) |
MX (1) | MX9606716A (ru) |
NO (1) | NO308303B1 (ru) |
NZ (1) | NZ299974A (ru) |
PT (1) | PT781776E (ru) |
RU (1) | RU2160739C2 (ru) |
SI (1) | SI0781776T1 (ru) |
SK (1) | SK283912B6 (ru) |
TW (1) | TW403753B (ru) |
ZA (1) | ZA9610892B (ru) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
US7276506B2 (en) * | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US6946465B2 (en) * | 1999-02-02 | 2005-09-20 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
US6303355B1 (en) * | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
EP1210350B1 (en) * | 1999-08-18 | 2004-07-14 | Wyeth | Water soluble sdz-rad esters |
AU2001247401A1 (en) * | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
AU2001249182A1 (en) * | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
US7300662B2 (en) * | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
EP1318837B1 (en) | 2000-08-11 | 2004-10-06 | Wyeth | Method of treating estrogen receptor positive carcinoma |
DE60136200D1 (de) * | 2000-09-19 | 2008-11-27 | Wyeth Corp | Wasserlösliche rapamycin-ester |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
MXPA03002871A (es) | 2000-09-29 | 2004-12-06 | Johnson & Johnson | Dispositivos medicos recubiertos. |
US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2296063T3 (es) | 2002-07-16 | 2008-04-16 | Biotica Technology Limited | Produccion de poliquetidos y otros productos naturales. |
CA2493878C (en) | 2002-07-30 | 2013-07-23 | Wyeth | Parenteral formulations containing a rapamycin hydroxyester |
US20040213757A1 (en) * | 2003-04-23 | 2004-10-28 | Wyeth Holdings Corporation | Water soluble wortmannin derivatives |
AU2004271721A1 (en) * | 2003-09-12 | 2005-03-24 | 4 Aza Bioscience Nv | Pteridine derivatives for the treatment of septic shock and TNF-alpha-related diseases. |
US20070032477A1 (en) * | 2003-10-17 | 2007-02-08 | Waer Mark J A | Pteridine derivatives useful for making pharmaceutical compositions |
ATE410431T1 (de) * | 2004-04-14 | 2008-10-15 | Wyeth Corp | Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper |
SG152234A1 (en) | 2004-04-14 | 2009-05-29 | Wyeth Corp | Regiospecific synthesis of rapamycin 42-ester derivatives |
BRPI0510277A (pt) * | 2004-04-27 | 2007-10-30 | Wyeth Corp | método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
RU2007112787A (ru) * | 2004-10-28 | 2008-12-10 | Вайет (Us) | ПРИМЕНЕНИЕ ИНГИБИТОРА mTOR ПРИ ЛЕЧЕНИИ ЛЕЙОМИОМЫ МАТКИ |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
GB0503936D0 (en) * | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
US7241771B2 (en) | 2005-03-07 | 2007-07-10 | Wyeth | Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
EP1896018A2 (en) | 2005-03-11 | 2008-03-12 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
CA2612788A1 (en) * | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
RS54088B1 (en) | 2005-07-25 | 2015-10-30 | Emergent Products Development Seattle Llc | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES |
WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
KR20080077989A (ko) * | 2005-12-20 | 2008-08-26 | 와이어쓰 | 약물의 불순물 조절을 통한 cci-779 제형의 안정성 조절 |
US7605257B2 (en) * | 2006-03-07 | 2009-10-20 | Wyeth | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
US8338435B2 (en) * | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
WO2008009079A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
AU2007339762B2 (en) * | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
NZ588671A (en) | 2008-04-11 | 2012-11-30 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
CN102292078A (zh) | 2008-11-11 | 2011-12-21 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
US20120010144A1 (en) * | 2009-04-03 | 2012-01-12 | Ragheb Assaly | Peg-albumin composition having at least one protected thiol region as a platform for medications |
IN2012DN02753A (ru) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
WO2011053938A1 (en) | 2009-10-30 | 2011-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
EP2563391B1 (en) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
GB201115665D0 (en) | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
EP3939572B1 (en) | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
WO2014059295A1 (en) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
AU2014265142A1 (en) | 2013-05-17 | 2015-12-24 | Medimmune, Llc | Receptors for B7-H4 |
BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA2943609A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
CA2950589A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3193902A4 (en) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | mTORC1 INHIBITORS |
MD20170081A2 (ru) | 2015-03-04 | 2018-03-31 | Gilead Sciences, Inc. | Соединения 4,6-диамино-пиридо [3,2 D] пиримидина модуляторы Толл подобных рецепторов |
WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
CA2997442C (en) | 2015-09-04 | 2021-01-26 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
GB201701087D0 (en) | 2017-01-23 | 2017-03-08 | Univ Leuven Kath | Novel prodrugs of mizoribine |
JP2020507632A (ja) | 2017-02-10 | 2020-03-12 | マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. | ラパマイシン類似体 |
ES2871499T3 (es) | 2017-05-15 | 2021-10-29 | Bard Inc C R | Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia |
EP3644997A1 (en) | 2017-06-26 | 2020-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
WO2019012024A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / - |
CN112368289B (zh) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | 作为mtor抑制剂的c26-连接的雷帕霉素类似物 |
CR20200578A (es) | 2018-05-01 | 2021-02-22 | Revolution Medicines Inc | Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor |
US20210115378A1 (en) | 2018-05-09 | 2021-04-22 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
EP3790592A1 (en) | 2018-05-09 | 2021-03-17 | Yale University | Particles for spatiotemporal release of agents |
EP3826650A4 (en) | 2018-07-23 | 2022-07-27 | Enclear Therapies, Inc. | METHODS OF TREATMENT OF NEUROLOGICAL DISEASES |
JP2022510573A (ja) | 2018-07-23 | 2022-01-27 | エンクリアー セラピーズ, インク. | 神経障害の治療方法 |
US20220047567A1 (en) | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of neurofibromatosis |
EP3880266A1 (en) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
US11116729B2 (en) | 2019-01-17 | 2021-09-14 | Georgia Tech Research Corporation | Drug delivery systems containing oxidized cholesterols |
WO2020209828A1 (en) | 2019-04-08 | 2020-10-15 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
AU2020271894A1 (en) | 2019-04-11 | 2021-12-02 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
CN116600789A (zh) | 2020-06-19 | 2023-08-15 | 耶鲁大学 | 用于诱导耐受性的聚合胆汁酸酯纳米颗粒 |
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4684728A (en) * | 1979-01-12 | 1987-08-04 | Bayer Aktiengesellschaft | Solubilizing biologically active compounds with reactive hydrogen atoms |
US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US4375464A (en) * | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
EP0429436A3 (en) * | 1985-12-06 | 1991-12-27 | The University Of Kansas | Prodrugs of rapamycin |
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
JP2631710B2 (ja) | 1988-08-16 | 1997-07-16 | 日本ヘキスト・マリオン・ルセル株式会社 | ピラノ〔f〕キノリノン誘導体及び該化合物を有効成分とする医薬組成物 |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5093338A (en) | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
WO1992021341A1 (en) * | 1991-05-31 | 1992-12-10 | Pfizer Inc. | Use of rapamycin prodrugs as immunosuppressant agents |
ATE135583T1 (de) * | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5169851A (en) * | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
AU681579B2 (en) * | 1992-03-30 | 1997-09-04 | Wyeth | Rapamycin formulation for IV injection |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
-
1996
- 1996-12-11 US US08/763,768 patent/US5780462A/en not_active Expired - Lifetime
- 1996-12-18 CA CA002193329A patent/CA2193329C/en not_active Expired - Fee Related
- 1996-12-18 CZ CZ19963734A patent/CZ293711B6/cs not_active IP Right Cessation
- 1996-12-19 MX MX9606716A patent/MX9606716A/es not_active IP Right Cessation
- 1996-12-19 NZ NZ299974A patent/NZ299974A/en unknown
- 1996-12-19 SK SK1638-96A patent/SK283912B6/sk unknown
- 1996-12-20 HU HU9603582A patent/HUP9603582A3/hu unknown
- 1996-12-20 ES ES96309369T patent/ES2189858T3/es not_active Expired - Lifetime
- 1996-12-20 AT AT96309369T patent/ATE233769T1/de not_active IP Right Cessation
- 1996-12-20 DE DE69626481T patent/DE69626481T2/de not_active Expired - Fee Related
- 1996-12-20 DK DK96309369T patent/DK0781776T3/da active
- 1996-12-20 SI SI9630585T patent/SI0781776T1/xx unknown
- 1996-12-20 PT PT96309369T patent/PT781776E/pt unknown
- 1996-12-20 EP EP96309369A patent/EP0781776B1/en not_active Expired - Lifetime
- 1996-12-23 NO NO965552A patent/NO308303B1/no unknown
- 1996-12-23 AU AU76517/96A patent/AU702750B2/en not_active Ceased
- 1996-12-23 ZA ZA9610892A patent/ZA9610892B/xx unknown
- 1996-12-24 TW TW085115988A patent/TW403753B/zh not_active IP Right Cessation
- 1996-12-24 CN CN96123983A patent/CN1088710C/zh not_active Expired - Fee Related
- 1996-12-24 KR KR1019960071130A patent/KR100444003B1/ko not_active IP Right Cessation
- 1996-12-25 RU RU96124399/04A patent/RU2160739C2/ru not_active IP Right Cessation
- 1996-12-26 AR ARP960105902A patent/AR005421A1/es active IP Right Grant
- 1996-12-26 JP JP34739396A patent/JP4080560B2/ja not_active Expired - Fee Related
- 1996-12-26 BR BR9606173A patent/BR9606173A/pt not_active IP Right Cessation
- 1996-12-26 IL IL11992196A patent/IL119921A/xx not_active IP Right Cessation
-
1998
- 1998-03-10 HK HK98101959A patent/HK1002864A1/xx not_active IP Right Cessation
- 1998-03-23 US US09/046,043 patent/US5955457A/en not_active Expired - Fee Related
-
2003
- 2003-09-10 CY CY0300062A patent/CY2377B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9603582D0 (en) | Water soluble rapamycin esters | |
PL323310A1 (en) | Rapamycin derivatives | |
AP9801250A0 (en) | Water disalination | |
HUP9900429A3 (en) | Expandible stent | |
NZ307170A (en) | Ascomycin derivatives | |
EP0816571A4 (en) | FOUNDATION | |
GB9521805D0 (en) | Solubilisation methods | |
GB9617204D0 (en) | Roulette | |
IL117858A0 (en) | 4-Indolypiperazinyl derivatives | |
PL322308A1 (en) | Automatic drawing-bench | |
IL125063A0 (en) | Water soluble antibiotics | |
GB2305617B (en) | Water filtering | |
GB2303409A8 (en) | Turbine | |
GB2300675B (en) | Turbines | |
GB9525077D0 (en) | Esters | |
GB9525417D0 (en) | Esters | |
EP0821767A4 (en) | RETENTION ELEMENT | |
GB9523183D0 (en) | Turbines | |
SI0833828T1 (en) | Rapamycin derivatives | |
BG99800U (en) | Chessboard set | |
IL114435A0 (en) | Water turbine | |
GB9511709D0 (en) | Drainage component | |
GB9514253D0 (en) | All-ways level | |
GB9510980D0 (en) | Level | |
GB9516823D0 (en) | Roulette |